To include your compound in the COVID-19 Resource Center, submit it here.
Vivalis S.A. (Euronext:VLS) will merge with infectious disease company Intercell AG (VSE:ICLL; OTCQX:INRLY) in a stock deal that values Intercell at about EUR 132.5 million ($174.4 million). The
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury